Topic: idiopathic pulmonary fibrosis
A year after tapping a former Yankees star for its "Breathless" push, Boehringer Ingelheim had another surprise for baseball fans this opening day.
Boehringer Ingelheim wants to move its drug nintedanib into the scleroderma market. Meanwhile, it’s working to expand awareness of the disease, too.
This week, both IPF drugmakers upped the ante with positive new data for their contenders at the American Thoracic Society's annual meeting.